Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.83 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Iofratol SCHEMBL381161 | 1.00 | LMNA (0.83) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL21479763 | 0.92 | LMNA (0.81) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| Iopamidol SCHEMBL27781 | 0.91 | LMNA (1.00) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| Iopamidol SCHEMBL471484 | 0.91 | LMNA (1.00) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| Iopamidol SCHEMBL7101453 | 0.91 | LMNA (1.00) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| SCHEMBL9352697 | 0.90 | LMNA (0.65) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL8844909 | 0.89 | LMNA (0.67) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL6211510 | 0.89 | LMNA (0.67) | LMNACYP2C19HIF1ASMN1; SMN2EGFR | |
| SCHEMBL14310826 | 0.88 | LMNA (0.83) | LMNACYP2C19HIF1ASMN1; SMN2 | |
| Iopamidol SCHEMBL2140144 | 0.87 | LMNA (0.92) | LMNACYP2C19HIF1ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260108355-A1 | DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY | ARTERIOCYTE MEDICAL SYSTEMS, INC. (US) | 2026-04-23 | — | — | US | disclosed |
| US-12521243-B2 | Demineralized bone fiber composition for use in minimally invasive surgery | ARTERIOCYTE MEDICAL SYSTEMS, INC. (US) | 2026-01-13 | — | — | US | disclosed |
| CN-119770722-A | Inorganic calcium salt composition, artificial bone material comprising same, drug-loaded artificial bone material and preparation method | 松山湖材料实验室 | 2025-04-08 | — | — | CN | disclosed |
| CN-119770723-A | Calcium salt granule composition, artificial bone material containing same, drug-loaded artificial bone material and preparation method | 松山湖材料实验室 | 2025-04-08 | — | — | CN | disclosed |
| US-11903835-B2 | Demineralized bone fiber composition for use in minimally invasive surgery | THERACELL, LLC (US) | 2024-02-20 | — | — | US | disclosed |
| US-20210251761-A1 | DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY | THERACELL, INC. (US) | 2021-08-19 | — | — | US | disclosed |
| US-10987224-B2 | Demineralized bone fiber composition for use in minimally invasive surgery | THERACELL, INC. (US) | 2021-04-27 | — | — | US | disclosed |
| US-20200397586-A1 | DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY | ARTERIOCYTE MEDICAL SYSTEMS, INC. | 2020-12-24 | — | — | US | disclosed |
| US-20200188122-A1 | DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY | ARTERIOCYTE MEDICAL SYSTEMS, INC. | 2020-06-18 | — | — | US | disclosed |
| US-10639157-B2 | Demineralized bone fiber composition for use in minimally invasive surgery | THERACELL, INC. (US) | 2020-05-05 | — | — | US | disclosed |
| EP-1829565-A1 | A new bone mineral substitute | Bone Support AB (SE) | 2007-09-05 | — | — | EP | disclosed |
| EP-1465678-B1 | A NEW BONE MINERAL SUBSTITUTE | BONE SUPPORT AB (SE) | 2007-06-27 | — | — | EP | disclosed |
| US-20070041906-A1 | Bone substitute composition | BONE SUPPORT AB (SE) | 2007-02-22 | — | — | US | disclosed |
| CN-1829543-A | A new bone substitute composition | BONE SUPPORT AB (SE) | 2006-09-06 | — | — | CN | disclosed |
| EP-1601387-A1 | A NEW BONE SUBSTITUTE COMPOSITION | Bone Support AB (SE) | 2005-12-07 | — | — | EP | disclosed |
| US-20050119746-A1 | Bone mineral substitute | BONE SUPPORT AB (SE) | 2005-06-02 | — | — | US | disclosed |
| EP-1465678-A1 | A NEW BONE MINERAL SUBSTITUTE | Bone Support AB (SE) | 2004-10-13 | — | — | EP | disclosed |
| WO-2004078223-A1 | A NEW BONE SUBSTITUTE COMPOSITION | BONE SUPPORT AB (SE) | 2004-09-16 | — | — | WO | disclosed |
| WO-2003053488-A1 | A NEW BONE MINERAL SUBSTITUTE | BONE SUPPORT AB (SE) | 2003-07-03 | — | — | WO | disclosed |
| US-5695742-A | MIXTURE OF NONIONIC ORGANIC COMPOUND COMPRISING TRIIODINATED AROMATIC NUCLEUS HAVING AMIDE SUBSTITUENTS AND COMPOUND COMPRISING TWO SUCH TRIIODINATED AROMATIC NUCLEI COVALENTLY BONDED TOGETHER | DIBRA S.P.A. (IT) | 1997-12-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070041906-A1 | Bone substitute composition | SOST, BMP2, BMP6 | LMNA 4402/4885CYP2C19 3675/4885HIF1A 2974/4885 |
| US-20260108355-A1 | DEMINERALIZED BONE FIBER COMPOSITION FOR USE IN MINIMALLY INVASIVE SURGERY | BMP2, COL2A1, COL1A1 | LMNA 1963/4885CYP2C19 1178/4885HIF1A 388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.